A biotech startup developing biofabricated, vascularized living tissue implants for clinical applications, with a long-term goal of producing functional bioprinted human organs.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €10 M | Mar, 2026 | seed |
Frequently Asked Questions
Where is Cellbricks Therapeutics located?
Cellbricks Therapeutics is located in Berlin, Germany.
What industries does Cellbricks Therapeutics operate in?
Cellbricks Therapeutics operates in the following industries: biotech, tissue engineering, bioprinting, regenerative medicine, medical devices.
How much total funding has Cellbricks Therapeutics raised?
Cellbricks Therapeutics has raised a total of $10,000,000.
Who are the investors in Cellbricks Therapeutics?
The investors in Cellbricks Therapeutics are: Silicon Roundabout, ACT Venture Partners, SPRIND (Federal Agency for Disruptive Innovation, Germany).
Who are the founders of Cellbricks Therapeutics?
The founders of Cellbricks Therapeutics are: Alexander Leutner.
What is the core mission of Cellbricks Therapeutics?
Cellbricks Therapeutics is dedicated to restoring lost tissue and organ function by developing advanced, cell-based human tissue therapeutics using high-resolution 3D bioprinting technology.
What proprietary technology does Cellbricks Therapeutics use for its medical solutions?
The company utilizes a proprietary light-based biofabrication system combined with AI-driven tissue engineering and custom bio-inks to create vascularized, immune-compatible human tissues at scale.
Which specific medical conditions is Cellbricks Therapeutics currently targeting?
Cellbricks Therapeutics is advancing two primary therapeutic programs: one focused on adipose tissue for wound healing and breast reconstruction, and a second program targeting liver tissue to restore organ function.
How does the bioprinting process at Cellbricks Therapeutics differ from traditional methods?
The company's light-based bioprinting approach is significantly faster than many other methods and eliminates shear stress on cells, which ensures high cell viability and the creation of large, complex, and vascularized tissue constructs.
Where are the primary operations of Cellbricks Therapeutics located?
Cellbricks Therapeutics is a preclinical biotech firm with operations based in both Berlin, Germany, and Boston, Massachusetts.
What is the ultimate long-term goal for Cellbricks Therapeutics?
Beyond its current focus on tissue implants for reconstructive surgery and wound care, the long-term ambition of the company is to manufacture fully functional, implantable human organs such as the liver.